source
- Evommune pays $30 million to Hinova for rights to develop oral VAV1 molecular glue degrader EVO570 outside ChinaEvommune announced a licensing agreement with Chinese firm Hinova Pharmaceuticals, paying $30 million upfront for access to a preclinical molecular glue program. The agreement gives Evommune the r…
- RevMed stock rises on early Rasonque sales as whistleblower sues Madrigal over MASH safetyRevMed announced its first sales figures for Rasonque, a therapy targeting pancreatic cancer, and the news sent the company's shares higher. The company said the early sales data reflect market up…